Beatty P - Search Results

1

Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.

Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, Pai RK, Singhi AD, Jacqueline CM, Bao R, Diergaarde B, McMurray RP, Strand C, Foster NR, Zahrieh DM, Limburg PJ, Finn OJ. Schoen RE, et al. Among authors: beatty p. Clin Cancer Res. 2023 May 1;29(9):1678-1688. doi: 10.1158/1078-0432.CCR-22-3168. Clin Cancer Res. 2023. PMID: 36892581 Free PMC article. Clinical Trial.

2

Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.

Beatty PL, Finn OJ. Beatty PL, et al. Ann N Y Acad Sci. 2013 May;1284:52-6. doi: 10.1111/nyas.12108. Ann N Y Acad Sci. 2013. PMID: 23651193

3

Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer.

Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Ma P, et al. Among authors: beatty pl. Front Immunol. 2019 Jun 19;10:1401. doi: 10.3389/fimmu.2019.01401. eCollection 2019. Front Immunol. 2019. PMID: 31275327 Free PMC article.

4

Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.

Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. Beatty PL, et al. Cancer Prev Res (Phila). 2010 Apr;3(4):438-46. doi: 10.1158/1940-6207.CAPR-09-0194. Epub 2010 Mar 23. Cancer Prev Res (Phila). 2010. PMID: 20332301 Free PMC article.

5

Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen.

Beatty P, Ranganathan S, Finn OJ. Beatty P, et al. Oncoimmunology. 2012 May 1;1(3):263-270. doi: 10.4161/onci.18950. Oncoimmunology. 2012. PMID: 22737601 Free PMC article.

6

Biochemical characterization of the soluble form of tumor antigen MUC1 isolated from sera and ascites fluid of breast and pancreatic cancer patients.

Beatty P, Hanisch FG, Stolz DB, Finn OJ, Ciborowski P. Beatty P, et al. Clin Cancer Res. 2001 Mar;7(3 Suppl):781s-787s. Clin Cancer Res. 2001. PMID: 11300473

7

Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer.

Beatty PL, Plevy SE, Sepulveda AR, Finn OJ. Beatty PL, et al. J Immunol. 2007 Jul 15;179(2):735-9. doi: 10.4049/jimmunol.179.2.735. J Immunol. 2007. PMID: 17617560

8

Cancer immunoprevention.

Finn OJ, Beatty PL. Finn OJ, et al. Curr Opin Immunol. 2016 Apr;39:52-8. doi: 10.1016/j.coi.2016.01.002. Epub 2016 Jan 19. Curr Opin Immunol. 2016. PMID: 26799207 Free PMC article. Review.

9

Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention.

Sivagnanalingam U, Beatty PL, Finn OJ. Sivagnanalingam U, et al. Mol Carcinog. 2020 Jul;59(7):852-861. doi: 10.1002/mc.23206. Epub 2020 Apr 25. Mol Carcinog. 2020. PMID: 32333615 Review.

10

Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis.

Kadayakkara DK, Beatty PL, Turner MS, Janjic JM, Ahrens ET, Finn OJ. Kadayakkara DK, et al. Pancreas. 2010 May;39(4):510-5. doi: 10.1097/MPA.0b013e3181bd6501. Pancreas. 2010. PMID: 20084048 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

429 results

Search Page